GH Research PLC

GHRS Healthcare Biotechnology

In the quarter to June 2026, EPS fell 53.3%, free cash flow fell 66.6% and total debt fell 97.9%, each against the same quarter a year earlier.

18.16 0.65 −3.46%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
28.70 23.04 34.13 28.32

+8 more quarters

Net Debt/EBITDA
18.73 14.32 16.87 17.50
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.23) (0.17) (0.20) (0.22)
Book value per Share
5.40 4.25 4.58 4.70
Free Cash Flow
(15.04) (10.73) (12.35) (13.72)
Other line items

Show all line items

Columns are period end dates